Background: Patients with cancer-associated thrombosis (CAT) have a high risk of recurrent venous thromboembolic events, which contribute to significant morbidity and mortality. Direct oral anticoagulants may provide a convenient treatment option for these patients. Objectives: To assess clinical characteristics and outcomes of patients with active cancer changing to rivaroxaban after ≥4 weeks of standard therapy for the treatment of venous thromboembolism (VTE) in clinical practice. This analysis focused on secondary outcomes of Cancer-associated thrOmboSIs – Patient-reported outcoMes with rivarOxaban (COSIMO). Patients: COSIMO was a multinational, prospective, noninterventional, single-arm cohort study. Overall, 505 patients received at least one dose of rivaroxaban; 96.6% changing from low-molecular-weight heparin, 1.6% from a vitamin K antagonist, and 1.8% from fondaparinux. Results: Most patients had solid tumors (n = 449; 88.9%) and approximately half of these patients had metastases. The qualifying venous thromboembolic event was deep vein thrombosis (DVT) in 45.3% of patients, pulmonary embolism (PE) in 37.2% of patients, DVT with PE in 9.7% of patients, and catheter-associated DVT in 7.5% of patients. Approximately 75.1% of patients received rivaroxaban for at least 3 months; 150 (29.7%) patients received concomitant chemotherapy during the study. VTE recurrence, major bleeding, nonmajor bleeding, and major adverse cardiovascular events occurred in 18 (3.6%), 18 (3.6%), 81 (16.0%), and 12 (2.4%) patients, respectively. Conclusions: In patients with CAT who changed to rivaroxaban treatment after ≥4 weeks of standard therapy, the observed incidence proportions of recurrent VTE and bleeding events were in keeping with the recognized effectiveness and safety profile of rivaroxaban for the treatment of CAT.

Maraveyas, A., Beyer-Westendorf, J., Lee, A., Mantovani, L., De Sanctis, Y., Abdelgawwad, K., et al. (2021). Cancer-Associated ThrOmboSIs – Patient-Reported OutcoMes With RivarOxaban (COSIMO) – Baseline characteristics and clinical outcomes. RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 5(8) [10.1002/rth2.12604].

Cancer-Associated ThrOmboSIs – Patient-Reported OutcoMes With RivarOxaban (COSIMO) – Baseline characteristics and clinical outcomes

Mantovani L. G.
Membro del Collaboration Group
;
2021

Abstract

Background: Patients with cancer-associated thrombosis (CAT) have a high risk of recurrent venous thromboembolic events, which contribute to significant morbidity and mortality. Direct oral anticoagulants may provide a convenient treatment option for these patients. Objectives: To assess clinical characteristics and outcomes of patients with active cancer changing to rivaroxaban after ≥4 weeks of standard therapy for the treatment of venous thromboembolism (VTE) in clinical practice. This analysis focused on secondary outcomes of Cancer-associated thrOmboSIs – Patient-reported outcoMes with rivarOxaban (COSIMO). Patients: COSIMO was a multinational, prospective, noninterventional, single-arm cohort study. Overall, 505 patients received at least one dose of rivaroxaban; 96.6% changing from low-molecular-weight heparin, 1.6% from a vitamin K antagonist, and 1.8% from fondaparinux. Results: Most patients had solid tumors (n = 449; 88.9%) and approximately half of these patients had metastases. The qualifying venous thromboembolic event was deep vein thrombosis (DVT) in 45.3% of patients, pulmonary embolism (PE) in 37.2% of patients, DVT with PE in 9.7% of patients, and catheter-associated DVT in 7.5% of patients. Approximately 75.1% of patients received rivaroxaban for at least 3 months; 150 (29.7%) patients received concomitant chemotherapy during the study. VTE recurrence, major bleeding, nonmajor bleeding, and major adverse cardiovascular events occurred in 18 (3.6%), 18 (3.6%), 81 (16.0%), and 12 (2.4%) patients, respectively. Conclusions: In patients with CAT who changed to rivaroxaban treatment after ≥4 weeks of standard therapy, the observed incidence proportions of recurrent VTE and bleeding events were in keeping with the recognized effectiveness and safety profile of rivaroxaban for the treatment of CAT.
Articolo in rivista - Articolo scientifico
active cancer; low‐molecular‐weight heparin; recurrent venous thromboembolism; rivaroxaban; vitamin K antagonist;
English
2021
5
8
e12604
open
Maraveyas, A., Beyer-Westendorf, J., Lee, A., Mantovani, L., De Sanctis, Y., Abdelgawwad, K., et al. (2021). Cancer-Associated ThrOmboSIs – Patient-Reported OutcoMes With RivarOxaban (COSIMO) – Baseline characteristics and clinical outcomes. RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 5(8) [10.1002/rth2.12604].
File in questo prodotto:
File Dimensione Formato  
10281-344387_VoR.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Creative Commons
Dimensione 632.13 kB
Formato Adobe PDF
632.13 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/344387
Citazioni
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
Social impact